A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

643

Participants

Timeline

Start Date

March 5, 2025

Primary Completion Date

April 30, 2028

Study Completion Date

April 30, 2028

Conditions
Obesity
Interventions
DRUG

Retatrutide

Administered SC

DRUG

Placebo

Administered SC

Trial Locations (53)

14226

Dent Neurosciences Research Center, Inc, Amherst

16635

Altoona Center For Clinical Research, Duncansville

23294

National Clinical Research, Inc, Richmond

27607

Care Access - Raleigh, Raleigh

28557

Carteret Medical Group, Morehead City

30062

Kubost Clinical Research - Marietta, Marietta

30189

North Georgia Clinical Research, Woodstock

32803

Charter Research - Winter Park, Orlando

33024

ALL Medical Research, LLC, Cooper City

33134

Florida International Medical Research, Coral Gables

33401

Metabolic Research Institute, Inc., West Palm Beach

34470

Renstar Medical Research, Ocala

37909

Alliance for Multispecialty Research, LLC, Knoxville

40213

L-MARC Research Center, Louisville

40509

Alliance for Multispecialty Research, LLC, Lexington

57701

Care Access - Rapid City, Rapid City

60523

Alliance for Multispecialty Research, LLC, Oak Brook

62703

Springfield Clinic Main Campus, Springfield

64114

Alliance for Multispecialty Research, LLC, Kansas City

70601

Care Access - Lake Charles (Bayou Pines), Lake Charles

70808

Pennington Biomedical Research Center, Baton Rouge

73160

Tekton Research, LLC., Moore

75149

Southern Endocrinology Associates, Mesquite

77054

Care Access - Houston, Houston

78229

Sleep Therapy Research Center, San Antonio

80045

University of Colorado Anschutz Medical Campus, Aurora

89128

Vector Clinical Trials, Las Vegas

92701

Southern California Clinical Research, Santa Ana

96817

Pacific Diabetes & Endocrine Center, Honolulu

98007

Northwest Clinical Research Center, Bellevue

98801

Central Washington Health Services Association d/b/a Confluence Health, Wenatchee

06517

CMR of Greater New Haven, LLC, Hamden

02114

Massachusetts General Hospital, Boston

L6T 0G1

Aggarwal and Associates Limited, Brampton

L7M 1K9

Circulate Cardiac & Vascular Centre, Burlington

L1E 2J5

Med Trust Research, Courtice

L8J 0B6

Winterberry Research Inc., Hamilton

J6X 4P7

Centre de Medecine Metabolique de Lanaudiere (CMML), Terrebonne

P7B 7C7

Care Access - Thunder Bay - Barton Street, Thunder Bay

M5G 1K2

Maple Leaf Research, Toronto

G8T 7A1

C.I.C. Mauricie inc., Trois-Rivières

B21 9RY

FutureMeds - Birmingham, Birmingham

BB2 1AX

Oakenhurst Medical Practice, Blackburn

FY3 7EN

Layton Medical Centre, Blackpool

BA15 1DQ

Bradford on Avon Health Centre, Bradford-on-Avon

CH62 6EE

FutureMeds - Liverpool, Bromborough

ST10 1NS

Cheadle Community Hospital, Cheadle

TW4 7NR

HMC Health Group - Meadows Centre for Health, Hounslow

OX4 1XB

St Bartholomew's Medical Centre, Oxford

TR18 3DX

Atlantic Medical, Penzance

BH16 5PW

The Adam Practice, Poole

S61 1AH

Woodstock Bower Surgery, Rotherham

PL11 2TB

Rame Group Practice, Torpoint

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT06859268 - A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity | Biotech Hunter | Biotech Hunter